Ming T. Tan’s Publications

  1. Yuan A, Chen XF, Zhou YZ and Tan MRobust subgroup analysis with semiparametric model in precision medicine.  Statistics Medicine, (Accepted) 2018.
  2. Zhuang Y, Tan M and Chen PY. A Novel Rank-based Non-parametric Method for Longitudinal Ordinal Data. (in press). Statistical Methods in Medical Research. 2017.
  3. Lynce FC, Barac A, Tan M, Asch, F, Smith KL, Dang C, Issacs C and Swain S. SAFE-HEART: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2 Positive Breast Cancer and Reduced Left Ventricular Function. The Oncologist. 2016. (in press). 2017 Mar 17. pii: theoncologist.2016-0412. doi: 10.1634/theoncologist.2016-0412. [Epub ahead of print].
  4. Yuan, A., Wang S and Tan MRobust Estimate of Regional Treatment Effect in Multi-regional Randomized Clinical Trial in Global Drug Development. Stat. & Its Interface. In Press. 2017.
  5. Yang Y, Fang HB, Roy A and Tan MAn Adaptive Oncology Phase I trial design of drug combinations with drug-drug interaction modeling. Statistics and Its Interface. (In press). 2017.
  6. Zhou W, Yuan A, Thieu T, Fang H and Tan TMPhase II Basket Group Sequential Clinical Trial with Binary Responses. Austin Biom and Biostat. 4(1): 1033. 2017.
  7. Wang S, Yuan A, Tang L, Fang HB, Tan MT and Chan L. ROC Analysis for Phase II Group Sequential Basket Clinical Trial. International Journal of Statistics in Medical Research, 2017, 6, 22-33.
  8. Deng, D., Fang, H.B., Jahromi, K., Song, J. and Tan, MDetecting the threshold points for gene expressions under multiple biological conditions. Statistics and Its Interface, In press. 2017
  9. Yuan A, Giurcanu M, Luta G, Tan MU-Statistics with Conditional Kernels for Incomplete Data Models. Annals of the Institute of Statistical Mathematics. 69:271–302, 2017. DOI 10.1007/s10463-015-0537-6.
  10. Yuan, A., Guo, Y., Shara, N.M., Howard, B.V., Tan, M.T. (2017). An additive Cox model for coronary heart disease study. Journal of Applied Statistics, In press.

  1. Lin HZ, Tan M and Y Li. Semi-parametrically efficient estimator of single-index varying coefficient Cox proportional model. Statistica Sinica. 26 (2016), 779- 807 doi:http://dx.doi.org/10.5705/ss.202015.0062.
  2. Huang P and Tan M. Multi-stage nonparametric tests for multidimensional mixed outcomes with nuisance treatment effect. Statistics and Its Interface. 9: 343–354. 2016.
  3. Gao Z, Roy A, and Tan MA Two-Stage Adaptive Targeted Clinical Trial Design for Biomarker Performance-Based Sample Size Re-Estimation. Statistics in Bioscience. DOI 10.1007/s12561-015-9139-3. 2016.
  4. Yuan A, Fang HB, and Tan MAdaptive Design for Staggered-Start Clinical Trial. Int. J. of Biostatistics. 16(2). 2016. DOI: https://doi.org/10.1515/ijb-2015-0011,
  5. Yuan A, Xiong M and Tan MU-Statistics for some nonparametric incomplete data models with side information. Intl J of Mathematics and Statistics. 17(1), 91-112, 2016.
  6. Yuan, A., Li, Q., Xiong, M., Tan, M.T. (2016). Adaptive design for staggered-start clinical trial. International Journal of Biostatistics, 12(2), https://doi.org/10.1515/ijb-2015-0011.
  7. Fang HB, Huang HZ, Clarke R, and Tan MPredicting multi-drug inhibition interactions based on signaling networks and single drug dose-response information. J. Comp Systems Biology 2(1): 101, 2016
  8. Yuan A, Zheng Y, Huang P and Tan MTA nonparametric test for the evaluation of group sequential clinical trials with covariate information. Journal of Multivariate Analysis, 152: 82-99, 2016.
  9. Tan M, Fang HB, Huang H, and Yang Y. Design and Statistical Analysis of Multidrug Combinations in Preclinical Studies and Clinical Trials. In Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. Page 215-234. Lin, J., Wang, B., Hu, X., Chen, K., Liu, R. (Eds.) Springer, New York & Switzerland, 2016.
  10. Wang Z, Yuan A and Tan MComputation of the properties of multi-stage clinical trial design based on SCPRT. J. of Clinical Trials. 6:4, 2016. DOI: 10.4172/2167-0870.1000274
  11. Chen F, Xue Y, Tan M and Chen P. Response to comment on” Efficient Statistical Tests to Compare Youden Index: Accounting for Contingency Correlation.” Statistics in Medicine. 35(4):637-40. 2016. doi: 10.1002/sim.6827.
  12. Pan SY, Tan MT, Zhang HP. Risk analysis and prevention in R&D alliance between Chinese and foreign pharmaceutical companies. IEEE International Conference on Management Science and Engineering. 22nd Conference Proceedings Part One. Page 809-817. 2016.
  13. Nalbantoglu S, Abu-Asab M, Tan M, Zhang X, Cai L and Amri H. Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis. OMICS A Journal of Integrative Biology. Volume 20, Number 7, 2016.
  14. Duan C, Cao YS, Zhou LZ, Tan M, Chen PS. A novel nonparametric confidence interval for differences of proportions for correlated binary data. Statistical Methods in Medical Research. DOI: 10.1177/0962280216679040. 2016.
  15. Zhou LZ, Yang XB, Guan Y, Xu X, Tan M, Hou FF, and Chen PY. Development and Validation of a Risk Score for Prediction of Acute Kidney Injury in Patients With Acute Decompensated Heart Failure: A Prospective Cohort Study in China. J Am Heart Assoc. 2016;5:e004035 doi: 10.1161/JAHA.116.004035
  16. Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM. Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC., Mann D, Strome SE and Edelman MJ. A Phase I Dose Escalation Trial of MAGE-A3 and HPV16 Specific Peptide Immunomodulatory Vaccines in Patients with Recurrent / Metastatic (RM) Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cancer Immunology, Immunotherapy. In press, 2015.
  17. Chen F, Xue Y, Tan M and Chen PY. Efficient Statistical Tests to Compare Youden Index: Accounting for Contingency Correlation. Statistics in Medicine. 34(9):1560-76. 2015. DOI: 10.1002/sim.6432
  18. Gao, Z, Roy, A and Tan, MMultistage adaptive biomarker-directed targeted design for randomized clinical trials.Contemp. Clinical Trials. DOI: 10.1016/j.cct.2015.03.001. 42:119-131. 2015.
  19. Fang HB, Chen XR, Pei XY, Grant S and Tan M. Experimental Design and Statistical Analysis for Multi-Drug Combination Studies. Statistical Methods in Medical Research, Feb., 2015. DOI: 10.1177/0962280215574320https://www.ncbi.nlm.nih.gov/pubmed/25744107
  20. Dromerick AW, Edwardson MA. Edwards DF, Giannetti ML, Barth J, Brady KP, Chan E, Tan MT, Tamboli I, Chia R, Kathaleen P, Chen E, Tan MT, Irfan, Orquiza M, Padilla RM, Cheema AK, Mapstone M, Fiandaca MS, Federoff HJ, and Newport EL. Critical Periods after Stroke Study: Translating animal stroke recovery experiments into a clinical trial. Frontiers in Human Neuroscience, 29 April 2015 |http://dx.doi.org/10.3389/fnhum.2015.00231
  21. Onukwugha E, Petrelli N, Castro K, Gardner J, Jayasekera J, Goloubeva O, Tan M, McNamara E, Zaren HA, Asfeldt T, Bearden J, Salner AL, Krasna MJ, Prabhu Das I, Clauser SB. The Impact of Multidisciplinary Care on Processes of Cancer Care: A Multi-Institutional Study. J. Clinical Oncology Practice. Published online 10.2015. 10.1200/JOP.2015.004200.
  22. G. Giaccone, L.A. Bazhenova1, J. Nemunaitis, M. Tan, E. Juhász, R. Ramlau, M.M. van den Heuvel, R. Lal, G.H Kloecker, K.D. Eaton, Q. Chu, D.J. Dunlop, M. Jain, E.B. Garon, C.S. Davis, E. Carrier, S.C. Moses, D.L. Shawler, H. Fakhrai. 2A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer“, European Journal of Cancer, Aug, 2015. DOI: 10.1016/j.ejca.2015.07.035
  23. Fiandaca MS, Zhong X, Cheema AK, Orquiza MH, Chidambaram S, Tan MT, Gresenz CR , FitzGerald KT, Nalls MA, Singleton AB, Mapstone M and Federoff HJ. Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer’s disease. Frontiers in Neurology published: 12 November 2015 doi: 10.3389/fneur.2015.00237.
  24. Yuan A, Giurcanu M, Luta G, Tan M. (2015) U-statistics with conditional kernels for incomplete data models. Annals of the Institute of Statistical Mathematics, doi: 10.1007/s10463-015-0537-6.
  25. Tan MConditional Power in Clinical Trial Monitoring, In “Handbook of Methods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential Methods”, edited by N. Balakrishnan, John Wiley & Sons, pp 102-110 (2014).
  26. Fang HB, Wu TT and Tan MSurvival Analysis with Functional Covariates for Partial Follow-up Studies. Statistical Methods in Medical Research. First published on February 24, 2014 as doi:10.1177/0962280214523586.
  27. Mapstone M, Cheema AK, Fiandaca MS, Zhong X,. Mhyre, TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, and Federoff HJ. Plasma phosphatidylcholines identify antecedent memory impairment in older adults. Nature Medicine. March 2014. doi:10.1038/nm.3466.
  28. Fang HB, Deng DL, Zhang T and Tan MModeling Sustained Treatment Effects in Tumor Xenograft Experiments. J. Biopharmaceutical Statistics. 24:755-769, 2014.
  29. Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson GA, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Medeiros J and Zaknoen SL. A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients. J. Clinical Oncology. (Dec 1). 2014. doi:10.1200/JCO.2014.55.5789
  30. Yuan A, Dromerick A and Tan MTPhase II multi-arm clinical trial designs and randomization with covariates via empirical weighting. Journal of Clinical Trials 4: 181. 2014.
  31. Huang P, Aihua O, Piantadosi S and Tan MFormulating Appropriate Statistical Hypotheses for Treatment Comparison in Clinical Trial Design and Analysis. Contemporary Clinical Trials. 39:294-302. 2014.
  32. Mapstone M, Fiandaca MS, Cheema AK, Zhong X, Tan MT, Kawas C, Federo, HJ. A Plasma-based Biomarker Panel Identies Preclinical Alzheimer’s Disease. Neurology April 8, 2014 vol. 82 no. 10 Supplement S38.001.
  33. Lin HZ, Li Y and Tan MEstimating a unitary effect summary based on combined survival and quantitative outcomes in clinical trials. Computational Statistics and Data Analysis, 66:129-139, 2013. (Epub on 4/28/2013. DOI: 10.1016/j.csda.2013.03.028.)
  34. Bao T, Cai L, Giles J, Gould J, Tarpinian K, Betts K, Medeiros M, Jeter S, Tait N, Chumsri S, Armstronge DK, Tan M, Folkerd E, Dowsett M, Singh H, Tkaczuk K and Stearns V. A Dual-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors. Breast Cancer Research and Treatment, 138(1):167-74. 2013.
  35. Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, Espinoza-Delgado I, and Ross DD. Translational phase I trial of vorinostat combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clinical Cancer Research, 19(7):1838-1851, 2013
  36. Zhao XF, Zhao MY, Cai L, Kukuruga D, Tan M, Stass SA. Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive large B-cell lymphomas. Int J Clin Exp Pathol. 6: 148-154, 2013.
  37. Yu H, Lu C, Tan M, Moudgil K. Comparative antigen-induced gene expression profiles unveil novel aspect of susceptibility/resistance to adjuvant arthritis in rats. Molecular Immunology, 51: 521-529, 2013.
  38. Bao T, Cai L, Snyder C, Betts K, Parpinian K, Gould J, Jeter S, Medeiros M, Chumsri S, Bardia A, Tan M, Singh H, Tkaczuk K and Stearns V. Patient Reported Outcomes in Women with Breast Cancer Enrolled in A Dual-Center Double Blind Randomized Controlled Trial Assessing the Effect of Acupuncture in Reducing Aromatase Inhibitor-induced Musculoskeletal Symptoms. DOI: 10.1002/cncr.28352. Cancer, 2013.
  39. Zhang Y, Meng X, Li A, Xin J, Berman BM, Lao L, Tan M, Ren K, Zhang RX. (2012). Electroacupuncture alleviates affective pain in an inflammatory pain rat model.European Journal of Pain.16(2):170-81.
  40. Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman BR, Papadimitriou JC, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE. (2012). Induction of mage-a3 and hpv-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head and Neck. DOI: 10.1002/hed.22004.
  41. Liu Z, Bensmail H, Tan M. (2012). Efficient feature selection and multiclass classification with integrated instance and model based learning. Evolutionary Bioinformatics. 8:1-10.
  42. Tkaczuk K, Tait NS, Ioffe OB, Tan M, Goloubeva O, Lesko SA, Deamond S, Zhou D, Lum ZP, Sutula MJ, Van Echo DA, Ts’o PO. (2011). Computer Assisted Quantitative Immunofluorescence of Tumor Tissue Marker Expression and Clinical Outcome to Chemotherapy in Advanced Breast Cancer Patients. Discovery Medicine. 12(68).
  43. Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, Lin W, Li G, Burch E, Tan M, Hertzano R, Chapoval A, Tamada K, Gastman B, Schulze DH, Strome SE (2010). CD137 promotes proliferation and survival of human B cell. J Immunol, 184:(2), 787-95.
  44. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV III, Sarlis N, Lorch J, Cullen KJ. (2009). Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res, 2:(9), 776-781.
  45. Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, et al. (2009). Beta-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol, 27:(36), 6222-8.
  46. Liu Z, Gartenhaus RB, Tan M, Jiang F, Jiao X. (2008). Gene and pathway identification with Lp penalized Bayesian logistic regression. BMC Bioinformatics, 9:(1), 412. PMCID: PMC2567351.
  47. Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ.(2008). Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res, 14:(18), 5877-83.
  48. Liu Z, Jiang F, Tian G-L, Wang S, Sato F, Meltzer SJ, Tan M.(2007). Sparse Logistic Regression with Lp Penalty for Biomarker Identification. Statistical Applications in Genetics and Molecular Biology, 6:(1):Article 6.
  49. Liu Z, Lin S, Tan M. (2006). Genome-wide tagging SNPs with entropy-based Monte Carlo method. J Comput Biol, 13:(9), 606-14.
  50. Tan M, Fang H-B, Tian G-L, Houghton PJ. (2003). Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med, 22:(13), 2091-100.
  51. Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, et al. (2003). A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res, 9:(2), 633-40.
  52. Marshall DR, Turner JT, Belz GT, Wingo S, Andreansky S, Sangster MY, Riberdy JM, Liu T, Tan M, Doherty PC. (2001). Measuring the dispora for virus specific CD8+T cellsProc Natl Acad Sci USA, 98:(11), 6313-8. PMCID: PMC33465.
  53. Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette C, Tan M, Friedman HS and Brent TP. (2000) . Antitumor activity of temozolomide combined with irinotecan is partly independent of MGMT and mismatch repair phenotypes in xenograft models.Clin Cancer Res., 6:4110-4118, 2000.
  54. Tan M, Xiong X, Kutner MH. (1998). Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing. Biometrics, 54(2), 682-95.
  55. Tan M, Xiong X. (1996). Continuous and group sequential conditional probability ratio tests for phase II clinical trials. Stat Med, 15:(19) 2037-51.
  56. Qu Y, Tan M, Kutner MH. (1996). Random-effects models in latent class analysis for evaluating accuracy of diagnostic tests. Biometrics, 52, 797-810.